T. Radivoyevitch

Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy
20234 citationsauthor #4
Identification of robust deep neural network models of longitudinal clinical measurements
202213 citationsauthor #6
Incidence, Clinical Features, and Outcomes of Langerhans Cell Histiocytosis in the United States
20228 citationsauthor #3
Chronic-Phase Chronic Myeloid Leukemia Times to Death By Disease Support Tyrosine Kinase Inhibitor Dose Reductions When BCR::ABL1 Level Is <1% and Decreasing
20221 citationsauthor #1
A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Anti-apoptotic Protein in Kidney Cancer
202215 citationsauthor #6
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
202212 citationsauthor #9
Addressing Therapeutic Inertia: Development and Implementation of an Electronic Health Record–Based Diabetes Intensification Tool
20223 citationsauthor #7
Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation
20210 citationsauthor #13
The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma
20216 citationsauthor #2
PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation
202114 citationsauthor #5
Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation
20213 citationsauthor #13
Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.
202168 citationsauthor #11
Uveal melanoma: Long-term survival
202118 citationsauthor #1
A Pharmacokinetic/Pharmacodynamic Model of the Action of Hypomethylating Agents in Chronic Myelomonocytic Leukaemia
20210 citationsauthor #2
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
202011 citationsauthor #7
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
20201 citationsauthor #9
Preclinical Modeling of Surgery and Steroid Therapy for Glioblastoma Reveals Changes in Immunophenotype that are Associated with Tumor Growth and Outcome
202028 citationsauthor #6
Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network
20201 citationsauthor #8
Estimating Cured Fractions of Uveal Melanoma.
202020 citationsauthor #3
A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
202045 citationsauthor #10
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
202040 citationsauthor #9
Distinctive and common features of moderate aplastic anaemia
202021 citationsauthor #9
The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia
20204 citationsauthor #10
A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.
202023 citationsauthor #8
Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
202085 citationsauthor #10
Conditional Survival in Uveal Melanoma.
202019 citationsauthor #2
Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries
20202 citationsauthor #1
Protons and high-LET radiation induce genetically similar lymphomas with high penetrance in a mouse model of the aging human hematopoietic system.
20207 citationsauthor #6
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes.
202063 citationsauthor #9
Genomics of therapy-related myeloid neoplasms
201936 citationsauthor #18
Do persons with chronic myeloid leukaemia have normal or near normal survival?
201936 citationsauthor #1
PBRM1 Loss in Kidney Cancer Unbalances the Kidney Lineage Master Transcription Factor Hub to Repress Terminal Epithelial Fates
20190 citationsauthor #4
Subclonal STAT3 mutations solidify clonal dominance.
201925 citationsauthor #10
The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy.
20192 citationsauthor #3
TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia
20193 citationsauthor #10
Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies
201916 citationsauthor #9
Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure
201914 citationsauthor #8
Bleeding incidence and risk factors among cancer patients treated with anticoagulation
2019123 citationsauthor #2
Tet 2 loss leads to hypermutagenicity in haematopoietic stem / progenitor cells
20197 citationsauthor #23
RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia
20192 citationsauthor #15
New drugs for pharmacological extension of replicative life span in normal and progeroid cells
20190 citationsauthor #2
5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively
20194 citationsauthor #4
Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.
201955 citationsauthor #17
Long-term trends in glioblastoma survival: implications for historical control groups in clinical trials.
201918 citationsauthor #2
New drugs for pharmacological extension of replicative life span in normal and progeroid cells
201910 citationsauthor #2
Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
20193 citationsauthor #3
SEER and Atomic Bomb Survivor Data Analysis Tools [R package SEERaBomb version 2019.2]
20190 citationsauthor #1
Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients
20190 citationsauthor #3
Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis
20190 citationsauthor #10
Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes
201954 citationsauthor #21
Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine
20190 citationsauthor #7
Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells
2019104 citationsauthor #12
Chronic myeloid leukemia: Two mysteries.
20193 citationsauthor #1
Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity
20192 citationsauthor #9
Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features
20190 citationsauthor #11
How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS
20191 citationsauthor #9
Treatment Outcomes of Cancer Associated Venous Thrombosis; The Cleveland Clinic Experience
20183 citationsauthor #4
Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.
2018161 citationsauthor #16
Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential
20181 citationsauthor #17
Chronic Myeloid Leukemia Incidence Based Estimates of Hematopoietic Stem Cell Numbers per Person
20180 citationsauthor #1
Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine
201835 citationsauthor #4
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.
201858 citationsauthor #1
Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States
20181 citationsauthor #2
Global immune fingerprinting in glioblastoma reveals immune-suppression signatures associated with prognosis
20182 citationsauthor #15
Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS)
20180 citationsauthor #10
Lessons from Nature: A Novel Class of TET Inhibitors for TET2 Mutant Associated Diseases
20181 citationsauthor #12
Distinct Features of Chip-Derived and De Novo MDS
20181 citationsauthor #15
Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria
201814 citationsauthor #7
Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia
20180 citationsauthor #9
IMMU-70. GLOBAL IMMUNE FINGERPRINTING IN GLIOBLASTOMA REVEALS IMMUNE-SUPPRESSION SIGNATURES ASSOCIATED WITH PROGNOSIS
20180 citationsauthor #15
Bleeding Rates and Risk Factors among Cancer and Non-Cancer Patients; A Comparison of Several Anticoagulants
20182 citationsauthor #2
Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies
20180 citationsauthor #15
LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes
20182 citationsauthor #12
Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes
20180 citationsauthor #17
Modulation of TET2 Activity By Ascorbic Acid and Factors Affecting Lysine Acetylation
20183 citationsauthor #6
How far have we really come? Trends in survival and mortality for gliomas between 1973 to 2014 from SEER.
20180 citationsauthor #2
Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes.
201850 citationsauthor #11
The evolution of paroxysmal nocturnal haemoglobinuria depends on intensity of immunosuppressive therapy
201820 citationsauthor #5
Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?
20181 citationsauthor #2
IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
201891 citationsauthor #2
Heterozygous CTC1 Variants in Acquired Bone Marrow Failure
20180 citationsauthor #5
Identification of gene expression determinants of radiosensitivity in bladder cancer (BCa) cell lines.
20181 citationsauthor #10
Poisson Regression Modeling of Chronic Myeloid Leukemia Mortality Trends
20180 citationsauthor #1
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates
2018102 citationsauthor #6
Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma
20185 citationsauthor #6
Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA
20180 citationsauthor #2
BRCA1 & BRCA2 Germline Variants Are Enriched in MDS/AML and Portend Higher Average Mutational Burden
20182 citationsauthor #9
Real‐world Experience with Decitabine Administered by a Non‐Cytotoxic, DNMT1‐Depleting Regimen in Patients with Myelodysplastic Syndromes: MDS‐048
20180 citationsauthor #6
Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms
201811 citationsauthor #10
Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations
20182 citationsauthor #5
Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure.
201815 citationsauthor #6
TP53 Mutations in Myeloid Neoplasms and Clonal Hematopoiesis of Indeterminate Potential following Cytotoxic Therapy for Antecedent Malignancy: MDS‐305
20180 citationsauthor #2
Genotype-Resultant Morphology of Myelodysplastic Syndromes (MDS)
20180 citationsauthor #13
A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia
201811 citationsauthor #9
Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL)
201887 citationsauthor #14
Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al.
20182 citationsauthor #3
Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia
20180 citationsauthor #11
Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML
20180 citationsauthor #13
Consequences of mutant TET2 on clonality and subclonal hierarchy
201856 citationsauthor #19
Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States
20180 citationsauthor #2

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT